With the characteristics of the Vaccine Industry that is “High Regulated and High Risk” requires continuous efforts to improve services to consumers. Bio Farma carries out various quality control (QC) procedures and ensures quality assurance consistently and continuously. Quality control and assurance procedures are monitored closely continuously by the National Regulatory Authority (NRA) which is recognized by WHO or in Indonesia known as the Drug and Food Control Agency (BPOM).
Vaccine manufacturing through a series of processes that are quite long by obeying aspects of the Clinical lots procedure, Current Good Manufacturing Practice (CGMP), Quality Control (QC) and Quality Service (QS). Before entering the stage of commercial production, three stages of strict clinical trials were carried out. Therefore, before vaccine products are marketed, regulations and ethics regarding the health and safety impacts of vaccine products have been fulfilled. The Company’s policy on consumers is stated in the Code of Business Conduct, which provides products and services that are of high quality and safe in their use, provide good services and are fair and without favoritism to consumers / customers and promote products properly and correctly. Bio Farma has never violated the rules for marketing communications through advertising, promotion or sponsorship. Bio Farma’s largest market segmentation in domestic is the Ministry of Health, which is a buyer of vaccine products to be distributed through the Public Health Office in 34 provinces in Indonesia. In addition Bio Farma also provides direct immunization services for individuals at the immunization center located in the company’s environment, as well as immunization services to company employees through a mechanism of cooperation with several institutions / companies (private sector).